Izraelis - anglų - Ministry of Health

masrouji co, ltd - somatropin recombinant - solution for injection - somatropin recombinant 5 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Europos Sąjunga - anglų - myHealthbox

pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

Europos Sąjunga - anglų - myHealthbox

pfizer limited - crizotinib - hard capsules - 250 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (as monohydrate) - leukemia, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukaemia (ph+ cml).cp, accelerated phase (ap), and blast phase (bp) ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - varenicline - tobacco use cessation - other nervous system drugs - champix is indicated for smoking cessation in adults.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - bazedoxifene - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

basilea pharmaceutica deutschland gmbh - isavuconazole - aspergillosis - cresemba is indicated in adults for the treatment of:invasive aspergillosismucormycosis in patients for whom amphotericin b is inappropriateconsideration should be given to official guidance on the appropriate use of antifungal agents.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - parecoxib sodium - pain, postoperative - coxibs, antiinflammatory and antirheumatic products - for the short-term treatment of postoperative pain in adults.,

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - anidulafungin - candidiasis - antimycotics for systemic use - treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

pfizer europe ma eeig - etanercept - spondylitis, ankylosing; arthritis, juvenile rheumatoid; arthritis, psoriatic; psoriasis; arthritis, rheumatoid - immunosuppressants - rheumatoid arthritis enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. juvenile idiopathic arthritis treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. enbrel has not been studied in children aged less than two years. psoriatic arthritis treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease. axial spondyloarthritis ankylosing spondylitis (as) treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. non-radiographic axial spondyloarthritis treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids). plaque psoriasis treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-a light (puva). paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,